These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 18753157

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
    Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, Harigai M, REAL Study Group.
    J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
    [Abstract] [Full Text] [Related]

  • 5. Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data.
    Keystone EC.
    J Rheumatol; 2011 Aug; 38(8):1552-62. PubMed ID: 21572154
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials.
    Thompson AE, Rieder SW, Pope JE.
    Arthritis Rheum; 2011 Jun; 63(6):1479-85. PubMed ID: 21360522
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. TNF antagonist safety in rheumatoid arthritis: updated evidence from observational registries.
    Nasir A, Greenberg JD.
    Bull NYU Hosp Jt Dis; 2007 Jun; 65(3):178-81. PubMed ID: 17922666
    [Abstract] [Full Text] [Related]

  • 13. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
    Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, Sundström C, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Klareskog L, Feltelius N.
    Ann Rheum Dis; 2005 Oct; 64(10):1414-20. PubMed ID: 15843454
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.
    Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Klareskog L.
    Ann Rheum Dis; 2005 Oct; 64(10):1421-6. PubMed ID: 15829572
    [Abstract] [Full Text] [Related]

  • 16. Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis.
    Ljung L, Simard JF, Jacobsson L, Rantapää-Dahlqvist S, Askling J, Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group.
    Arthritis Rheum; 2012 Jan; 64(1):42-52. PubMed ID: 21898355
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis.
    Seminari E, De Silvestri A, Boschi A, Tinelli C.
    AIDS Rev; 2008 Jan; 10(4):236-44. PubMed ID: 19092979
    [Abstract] [Full Text] [Related]

  • 19. TNF-alpha antagonism and cancer risk in rheumatoid arthritis: is continued vigilance warranted?
    Park HJ, Ranganathan P.
    Discov Med; 2012 Mar; 13(70):229-34. PubMed ID: 22463799
    [Abstract] [Full Text] [Related]

  • 20. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.
    Jacobsson LT, Turesson C, Gülfe A, Kapetanovic MC, Petersson IF, Saxne T, Geborek P.
    J Rheumatol; 2005 Jul; 32(7):1213-8. PubMed ID: 15996054
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.